Multicolor PET to interrogate cancer biology

多色 PET 探索癌症生物学

基本信息

  • 批准号:
    10598692
  • 负责人:
  • 金额:
    $ 65.99万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-05-01 至 2027-03-31
  • 项目状态:
    未结题

项目摘要

SUMMARY: The problem: In molecular medicine multiple parameters are combined for a more inclusive evaluation towards personalized medicine. A thorough characterization of a patient’s tumor upfront provides better outcomes, i.e., better insight affords higher survival rates. In contrast and almost anachronistically, PET imaging (the most sensitive and quantitative imaging method) is “monochromatic” as it can only assess one parameter at the time, lacking depth of information. Suitable imaging tools that allow visualization of more than one target in patients are needed, akin an in vivo cytometry. Optical imaging utilizes multiple parts of the spectrum to visualize several targets simultaneously, but this is not feasible for whole-body clinical imaging due to the limited penetration of light. Single-photon emission computed tomography (SPECT) can distinguish several isotopes based on the energy of their emissions, but spectra often overlap and the required collimation significantly decreases sensitivity. Different tracers could be imaged sequentially with PET but multiple scans increase the dose exposure from the required CT scans. It also requires sufficient decay of one tracer over time to be able to image the remaining one, decreasing convenience for patients. For three or four different isotopes this requires an even more complex coordination. As a solution, we propose the new modality of multicolor PET (mPET), which allows for simultaneous PET acquisitions of up to four different radiotracers at the same time. This new imaging paradigm utilizes one standard (pure) positron emitter together with positron-gamma emitters that produce triple (positron-gamma) coincidences, where a prompt gamma emission immediately follows the positron and identifies the isotope. We already imaged two isotopes in a standard PET scanner with the aid of the additional gamma signal but without energy discrimination. Here, we utilize the energy of the gamma signal as “barcode identifier” for the corresponding isotope while the spatial information is carried with the 511 keV annihilation photons. The prompt gamma requires detection without spatial decoding, which is achieved by an add-on gamma detector with sufficient energy discrimination and temporal resolution that is synchronized with the PET scanner. We established this system already and imaged three isotopes together. Here, we will in Aim 1 optimize the mPET set-up and then employ mPET to address important clinical/biological problems: In Aim 2, we will dissect the tumor microenvironment, interrogating signatures important for prognosis. In Aim 3, we will use mPET to interrogate important players in checkpoint inhibition therapy (CD4+ / CD8+ / PD-L1 / macrophages) simultaneously over time to predict response and will explore cellular therapies by following the injected cells to their target. The overall impact of this study will be significant, as mPET represents a true paradigm shift, allowing imaging of several radiotracers simultaneously. We demonstrate the power of this novel approach with clinically relevant approaches. More tracers asses a tumor better than one tracer alone, will provide a deeper insight into relevant tumor signatures, resulting in improved patient outcome.
摘要:问题是:在分子医学中,多个参数被结合在一起以获得更广泛的结果

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jan Grimm其他文献

Jan Grimm的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jan Grimm', 18)}}的其他基金

Cerenkov 2.0 – Cerenkov-activated agents for imaging and therapy
Cerenkov 2.0 — 用于成像和治疗的 Cerenkov 激活剂
  • 批准号:
    10644155
  • 财政年份:
    2022
  • 资助金额:
    $ 65.99万
  • 项目类别:
Exploiting ferroportin for cancer imaging and therapy
利用铁转运蛋白进行癌症成像和治疗
  • 批准号:
    10170300
  • 财政年份:
    2017
  • 资助金额:
    $ 65.99万
  • 项目类别:
Exploring PSMA Biology in Tumor neovasculature
探索肿瘤新生血管中的 PSMA 生物学
  • 批准号:
    9380403
  • 财政年份:
    2017
  • 资助金额:
    $ 65.99万
  • 项目类别:
Smart and self-reporting clinical nano carriers for drug delivery
用于药物输送的智能和自我报告的临床纳米载体
  • 批准号:
    9302146
  • 财政年份:
    2017
  • 资助金额:
    $ 65.99万
  • 项目类别:
Cerenkov-emission based nanosensors to detect biologic activities in vivo
基于切伦科夫发射的纳米传感器检测体内生物活性
  • 批准号:
    8788930
  • 财政年份:
    2012
  • 资助金额:
    $ 65.99万
  • 项目类别:
Cerenkov-emission based nanosensors to detect biologic activities in vivo
基于切伦科夫发射的纳米传感器检测体内生物活性
  • 批准号:
    8276113
  • 财政年份:
    2012
  • 资助金额:
    $ 65.99万
  • 项目类别:
Cerenkov-emission based nanosensors to detect biologic activities in vivo
基于切伦科夫发射的纳米传感器检测体内生物活性
  • 批准号:
    8441561
  • 财政年份:
    2012
  • 资助金额:
    $ 65.99万
  • 项目类别:
Cerenkov-emission based nanosensors to detect biologic activities in vivo
基于切伦科夫发射的纳米传感器检测体内生物活性
  • 批准号:
    8607183
  • 财政年份:
    2012
  • 资助金额:
    $ 65.99万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了